IP Verse

Immunotherapy Using Redirected Allogeneic Cells - EP2566954

The patent EP2566954 was granted to Yeda Research on Nov 2, 2022. The application was originally filed on May 4, 2011 under application number EP11778231A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2566954

YEDA RESEARCH
Application Number
EP11778231A
Filing Date
May 4, 2011
Status
Patent Maintained As Amended
Sep 30, 2022
Grant Date
Nov 2, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GRUNDMay 27, 2019GRUND -

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO0031239
OPPOSITIONEP2566954
OPPOSITIONUS2008267972
OPPOSITIONUS6544787
OPPOSITIONUS7943180
OPPOSITIONWO2011140170

Non-Patent Literature (NPL) Citations (32) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- COPELAN A. Edward, "Hematopoietic stem- cell transplantation", N Engl J Med, (20060000), vol. 354, pages 1813 - 1826, XP055606266-
OPPOSITION- KARRE, "NK cells, MHC class 1 molecules and the missing self", Scand J Immunol, (20020300), vol. 55, no. 3, pages 221 - 228, XP055606253-
OPPOSITION- MARCUS et al., "Tumor immunotherapy using chimeric receptor redirected allogeneic T cells across MHC barriers", J Immunol, (20100401), vol. 184, no. Supp 1, page 131.39-
OPPOSITION- MARCUS et al., "Tumor immunotherapy using chimeric receptor redirected allogeneic T cells across MHC barriers", J Immunol, (20100401), vol. 184, no. Supp 1, page 131.39, XP055606255-
OPPOSITION- ESHHAR, "The T-body approach: redirecting T cells with antibody specificity", ESHHAR, ESHHAR Z., Therapeutic Antibodies. Handbook of Experimental Pharmacology, Springer- Verlag, (20080000), vol. 181, pages 329 - 338, XP055606267
OPPOSITION- BACIGALUPO et al., "Defining the intensity of conditions regimens: working definitions", Biol Blood Marrow Transplant, (20091215), vol. 15, doi:10.1016/j.bbmt.2009.07.004, pages 1628 - 1633, XP026739009
OPPOSITION- CAHALAN et al., "Imaging the choreography of lymphocyte trafficking and the immune response", Curr Opin Immunol, (20060800), vol. 18, no. 4, doi:10.1016/j.coi.2006.05.013, pages 1 - 10, XP025079086
OPPOSITION- KANG et al., "Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model.", Exp Hematol, (20060200), doi:10.1016/j.exphem.2005.10.010, pages 132 - 139, XP025017413
OPPOSITION- KLEBANOFF et al., "Sinks, supressors and antigen presenters: how lymphodepletion D15 enhances T cell -mediated tumor immunotherapy", Trends Immunology, (20050200), vol. 26, no. 2, pages 111 - 117, XP004724117
OPPOSITION- HAGA et al., "Permanent, lowered HLA class I expression using lentivirus vectors with D14 shRNA constructs: averting cytotoxicity by alloreactive T lymphocytes", Transplant Proc, (20061200), vol. 38, no. 10, doi:10.1016/j.transproceed.2006.10.158, pages 3184 - 3188, XP025007998
OPPOSITION- ROUAS-FREISS et al., "HLA-G in transplantation: a relevant molecule for inhibition of graft rejection?", Am J Transplant, (20030000), vol. 3, doi:10.1034/j.1600-6143.2003.30103.x, pages 11 - 16, XP002522098
OPPOSITION- MATLOUBIAN et al., "Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1", Nature, (20040122), vol. 427, doi:10.1038/nature02284, pages 355 - 360, XP002357815
OPPOSITION- MURANSKI et al., "Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go?", Nat Clin Pract Oncol, (20061200), vol. 3, no. 12, doi:10.1038/ncponc0666, pages 668 - 681, XP009089821
OPPOSITION- LEY et al., "Signals for lymphocyte egress", Nature Immunol, (20051200), vol. 6, no. 12, pages 1215 - 1216, XP055606108
OPPOSITION- WEI et al., "Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial D10 migration of medullary T cells to lymphatic sinuses", Nature Immunol, (20051200), vol. 6, no. 12, doi:10.1038/NI1269, pages 1228 - 1235, XP002511848
OPPOSITION- POPAT et al., "Outcome of reduced-intensity allogeneic hematopoietic stem cell D16 transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML", Bone Marrow Transplant, (20060300), vol. 37, no. 6, pages 547 - 552, XP055606258
OPPOSITION- ESHHAR et al., "Specific activation and targeting of cytotoxic lymphocytes through D28 chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T- cell receptors", Proc Natl Acad Sci, (19930100), vol. 90, doi:10.1073/pnas.90.2.720, pages 720 - 724, XP002009770
OPPOSITION- BRINKMANN et al., "The immune modulator FTY720 targets sphingosine 1-Phosphate receptors", J Biol Chem, (20020614), vol. 277, no. 24, doi:10.1074/jbc.C200176200, pages 21453 - 21457, XP002264445
OPPOSITION- GATTINONI et al., "Removal of homeostatic cytokine sinks by lymphodepletion enhances D17 the efficacy of adoptively transferred tumor-specific CD 8+ T cells", J Exp Med, (20051003), vol. 202, no. 7, pages 907 - 912, XP055606260
OPPOSITION- DOTTI et al., "Fiteen years of gene therapy based on chimeric antigen receptors: Are we nearls there yet?", Hum Gene Ther, (20091100), vol. 20, pages 1229 - 1239, XP055122213
OPPOSITION- SHIMIZU et al., "KRP-203, a novel synthetic immunosuppressant, prolongs graft survival D11 and attenuates chronic rejection in rat skin and heart allografts", Circulation, (20050118), vol. 111, no. 2, pages 222 - 229, XP002408357
OPPOSITION- KIM et al., "Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.", J Clin Invest, (20030300), vol. 111, no. 5, pages 659 - 669, XP055606114
OPPOSITION- FRAUWIRTH et al., "Activation and inhibition of lymphocytes by costimulation", J Clin Invest, (20020201), vol. 109, no. 3, pages 295 - 299, XP055606262
OPPOSITION- TAYLOR et al., "Insights into the mechanism of FTY720 and compatibility with regulatory T D5 cells for the inhibition of graft-versus-host disease (GVHD", Blood, (20070702), vol. 110, no. 9, doi:10.1182/blood-2007-05-087940, pages 3480 - 3488, XP055117725
OPPOSITION- CONDOMINES et al., "Increased plasma-immune cytokines throughout the high-dose D19 melphalan-induced lymphodepletion in patients with multiple lyeloma: a window for adoptive immunotherapy", J Immunol, (20091204), vol. 184, no. 2, pages 1079 - 1084, XP055606261
OPPOSITION- KINTER et al., "The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands", J Immunol, (20081115), vol. 181, no. 10, pages 6738 - 46, XP055606263
SEARCH- WRZESINSKI C ET AL, "Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 17, no. 2, ISSN 0952-7915, (20050401), pages 195 - 201, (20050401), XP027787172 [A] 1-15 * the whole document *-
SEARCH- ESHHAR Z, "The T-body approach: redirecting T cells with antibody specificity", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, (20080101), no. 181, doi:10.1007/978-3-540-73259-4, ISSN 0171-2004, pages 329 - 342, XP009106856 [A] 1-15 * the whole document *
SEARCH- JOHANNES L ZAKRZEWSKI ET AL, "Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors", NATURE BIOTECHNOLOGY, (20080401), vol. 26, no. 4, doi:10.1038/nbt1395, ISSN 1087-0156, pages 453 - 461, XP055078646 [A] 1-15 * the whole document *
SEARCH- FRIEDMANN-MORVINSKI DINORAH ET AL, "Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 8, doi:10.1182/BLOOD-2004-09-3737, ISSN 0006-4971, (20050415), pages 3087 - 3093, (20040927), XP002499220 [A] 1-15 * the whole document *
SEARCH- A. BONI ET AL, "Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers", BLOOD, (20081201), vol. 112, no. 12, doi:10.1182/blood-2008-07-169797, ISSN 0006-4971, pages 4746 - 4754, XP055034897 [A] 1-15 * the whole document *
SEARCH- MARCUS ASSAF ET AL, "Redirected tumor-specific allogeneic T cells for universal treatment of cancer", BLOOD, (201107), vol. 118, no. 4, pages 975 - 983, XP002712636 [T] * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents